Major News/Events :

Future Waves Design Win -- May 2007

Key Development Milestone -- Feb 2007

Toumaz Wins Oracle Award -- Dec 2006


Nanoscience Inc, is a specialist niche investor in emerging technologies with
strong commercial propositions from within the growing nanotechnology sector.

Web Sites of companies in which NAN has an interest :

http://www.toumaz.com/

http://www.f-waves.com/

http://www.appliedsensor.com

http://www.xrt.com.au/

Nanoscience Inc
11 April 2008

Nanoscience Inc.
('Nanoscience' or the 'Group')

Toumaz Technology As Part of Consortium That Wins 7.1 million European
Community Grant

Nanoscience, the specialist niche investor in emerging technologies with strong
commercial propositions for the healthcare and electronic sectors, is pleased to announce that its wholly-owned subsidiary Toumaz Technology Limited ('Toumaz'), is part of a major collaborative research project that has been awarded a 7.1 million grant to fund the development of a portable blood glucose predictor system for diabetes patients.

The Personal Glucose Predictive Diabetes Advisor ('DIAdvisorTM') system is a
unique personalised blood glucose prediction tool that allows patients at any
time to actively and accurately predict their short-term blood glucose outlook
by the analysis of data retrieved from glucose measurements, insulin delivery
data and specific patient parameters, which will be captured by non-intrusive
body-worn wireless monitors based on Toumaz's breakthrough SensiumTM platform.

The grant award, made under the Seventh Framework Programme (FP7) of the
European Community, will fund the four-year research and development project
into the DIAdvisorTM system. The large-scale project is being coordinated by
Novo Nordisk A/S, a world leader in diabetes care, and will be delivered by a
consortium of 13 medical, industrial and academic partners, including the
European Division of the International Diabetes Federation.

Toumaz's role in the project will be to implement the DIAdvisorTM hardware and
software platform, leverage the SensiumTM intelligent data acquisition platform
and networking infrastructure to enable multiple vital signs measurements from
non-intrusive body-worn monitors to be taken and merged with manually entered '
spot' measurements (such as food intake), providing the key data for the
creation of physiological mathematical modeling, control and prediction
algorithms. The resulting analysis and prediction information will then be able
to be wirelessly transmitted to a healthcare provider advisory service, with
recommended action and treatment advice presented to the patient via a handheld
mobile device such as a Personal Digital Assistant (PDA).

First stage data gathering and clinical trials are planned to start in August
2008, with initial data expected by the end of the year.

Dr Alison Burdett, Director of Technology for Toumaz commented:

'With DIAdvisorTM, we will be putting a sophisticated treatment advisor in the
hands of patients for the first time, empowering them in their own healthcare
management and significantly reducing the likelihood of serious complications
and recurrent hospitalisation due to poor glucose control. For healthcare
providers, DIAdvisorTM will have a significant positive impact on cost reduction for the treatment of diabetes.'

Guy Spelman CEO of Nanoscience commented:

'This is further good news from our investment in Toumaz and its development of
the SensiumTM platform. Recognition of the growing importance of the SensiumTM
platform in more sectors in the field of medicine provides further evidence of
its versatility and increasing acceptance across global leaders and government
bodies.'


- Ends -